Viatris Phase 3 Japan trial of kidney drug VR-205 meets primary endpoint

June 29, 2026 6:59 AM

Viatris Inc. (Nasdaq: VTRS) announced positive top-line results from a Phase 3 clinical trial of VR-205, a targeted-release budesonide formulation ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found